Drugs that contain Pirfenidone
1. Esbriet patents expiration
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561217 | GENENTECH INC | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(2 years ago) | |
| US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
| US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US7696326 | GENENTECH INC | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(3 years from now) | |
| US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(3 years from now) | |
| US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(4 years from now) | |
| US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
| US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(5 years from now) | |
| US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(5 years from now) | |
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for day...
Dosage: TABLET;ORAL
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
